Trial Profile
A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-12 (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 07 Sep 2006 Status change
- 17 Sep 2005 New trial record.